Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.

1'-Methyl-4'-(1-naphth-yl)-1'',2'',3'',4''-tetra-hydro-indane-2-spiro-2'-pyrrolidine-3'-spiro-2''-naphthalene-1,3,1''-trione. Acta Crystallogr Sect E Struct Rep Online (2011) 1.29

(3aR,8bR)-3a,8b-Dihy-droxy-1-(4-meth-oxy-phen-yl)-2-methyl-sulfan-yl-3-nitro-1,8b-di-hydro-indeno-[1,2-b]pyrrol-4(3aH)-one. Acta Crystallogr Sect E Struct Rep Online (2013) 0.83

Methyl 3-[(1H-benzimidazol-1-yl)meth-yl]-1-methyl-4-(4-methyl-phen-yl)-2'-oxopyrrolidine-2-spiro-3'-1-benzimidazole-3-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online (2010) 0.75

3'-[Hy-droxy(4-oxo-4H-chromen-3-yl)meth-yl]-2-oxospiro-[indoline-3,2'-pyrrolidine]-3'-carbonitrile. Acta Crystallogr Sect E Struct Rep Online (2011) 0.75

Deoxysugars as antituberculars and alpha-mannosidase inhibitors. Antimicrob Agents Chemother (2014) 0.75

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

IFNalpha activates dormant haematopoietic stem cells in vivo. Nature (2009) 7.17

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst (2007) 4.14

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA (2011) 3.92

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13

Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy. Radiology (2012) 2.36

Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev (2007) 2.34

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood (2009) 2.28

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst (2005) 2.09

Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension (2004) 1.89

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol (2004) 1.82

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood (2010) 1.70

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol (2006) 1.66

Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics (2006) 1.53

Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet (2005) 1.53

Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res (2005) 1.50

Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood (2004) 1.44

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer (2006) 1.42

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35

Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis (2004) 1.31

Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One (2009) 1.30

Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol (2005) 1.27

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood (2006) 1.27

Abscisic acid is an endogenous stimulator of insulin release from human pancreatic islets with cyclic ADP ribose as second messenger. J Biol Chem (2008) 1.26

Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J Biol Chem (2006) 1.24

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23

Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22

The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol (2007) 1.18

Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB-IIA1). Gynecol Oncol (2011) 1.17

Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation (2008) 1.16

LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells. J Biol Chem (2009) 1.15

Retracted Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity (2003) 1.15

Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol (2006) 1.14

Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets (2013) 1.12

Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Ann Neurol (2014) 1.11

The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem (2012) 1.11

Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J (2004) 1.11

Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res (2007) 1.10

Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology (2008) 1.10

The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging (2007) 1.09

Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induction and limitations of neonatal antibody responses to T-dependent antigens. J Immunol (2003) 1.08

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother (2012) 1.06

Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst (2011) 1.05

Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04

Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res (2005) 1.03

The association of human mesenchymal stem cells with BMP-7 improves bone regeneration of critical-size segmental bone defects in athymic rats. Bone (2010) 1.02

Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist (2009) 1.02

Paramecium bursaria Chlorella virus 1 encodes two enzymes involved in the biosynthesis of GDP-L-fucose and GDP-D-rhamnose. J Biol Chem (2003) 1.02

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer (2011) 1.02

Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des (2013) 1.01

The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB J (2011) 1.01

Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis (2005) 1.01

Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep (2006) 1.00

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol (2015) 0.99

Organosulfur compounds: electrophilic reagents in transition-metal-catalyzed carbon-carbon bond-forming reactions. Angew Chem Int Ed Engl (2005) 0.99

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet (2008) 0.99

Autophagy in blood cancers: biological role and therapeutic implications. Haematologica (2013) 0.99

Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist (2007) 0.98

The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol (2006) 0.97

Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist (2008) 0.97

Recent synthetic approaches toward non-anomeric spiroketals in natural products. Molecules (2008) 0.97

Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat (2013) 0.97

High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood (2011) 0.97